Ashland Inc. (ASH) Market Cap & Valuation Ratios
Ashland Inc. (ASH) has a market cap of $3.3B, a trailing P/E of 69.5 and a price-to-sales ratio of 1.8, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ASHAshland Inc.Follow ASH — free
—
Price chart with a free account
- Market cap
- 3.3B
- P/E TTM
- 69.5
- Dividend yield
- 2.2%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
specialty chemicals · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ASH | 3.3 | 69.5 | 2.3 | 13.0 | 7.5% | -1% | 7% | 3% |
| PRM | 4.6 | — | 7.5 | — | 2.1% | +24% | -51% | -20% |
| CLMT | 4.3 | — | 1.4 | 34.2 | 1.7% | +13% | 1% | 3% |
| CBT | 3.8 | 20.7 | 1.3 | 7.2 | 7.4% | -5% | 14% | 10% |
| AVNT | 3.8 | 22.2 | 1.6 | 10.3 | 5.1% | +2% | 9% | 6% |
| WDFC | 2.9 | 32.3 | 4.3 | 22.6 | 2.8% | +10% | 17% | 29% |
| HWKN | 2.8 | 34.3 | 2.7 | 17.3 | 3.3% | +9% | 11% | 12% |
| KWR | 2.7 | 27.8 | 1.7 | 13.5 | 2.8% | +8% | 8% | 5% |
| FUL | 2.7 | 13.8 | 1.3 | 7.9 | 3.7% | +1% | 11% | 7% |
| IOSP | 2.4 | 20.1 | 1.2 | 12.8 | 2.0% | +3% | 7% | 10% |
| NGVT | 2.4 | 46.4 | 3.0 | 6.7 | 6.5% | -1% | 36% | 29% |
| Median of these 10 | 25.0 | 1.6 | 12.8 | 3.1% | +5% | 10% | 9% |
P/E 69.5 vs. a peer median of 25.0; EV/Sales 2.3 vs. 1.6. ASH's own P/E sits at the 96th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesPRM and CLMT have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Ashland Inc. — questions
- What is Ashland Inc.'s market cap?
- $3.3B.
- What is Ashland Inc.'s P/E ratio?
- 69.5 on trailing twelve-month earnings to 2026-06-30.
- What is Ashland Inc.'s price-to-sales ratio?
- 1.8.
Every figure on this page comes from Ashland Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.